Robert J Norman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3888732/publications.pdf

Version: 2024-02-01

400 papers

51,919 citations

99 h-index 216 g-index

414 all docs

414 docs citations

times ranked

414

21655 citing authors

#	Article	IF	CITATIONS
1	Letter to the Editor from Teede: "Clinical Practice Guidelines on the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Review and Quality Assessment Studyâ€, Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1321-e1322.	1.8	O
2	Intracytoplasmic sperm injection for all or for a few?. Fertility and Sterility, 2022, 117, 270-284.	0.5	4
3	Population-wide contribution of medically assisted reproductive technologies to overall births in Australia: temporal trends and parental characteristics. Human Reproduction, 2022, 37, 1047-1058.	0.4	19
4	Development of children born from IVM versus IVF: 2-year follow-up of a randomized controlled trial. Human Reproduction, 2022, 37, 1871-1879.	0.4	10
5	Immunology in reproductive medicine: is current testing and therapy justified by science?. Fertility and Sterility, 2022, , .	0.5	O
6	The Classification of Polycystic Ovary Syndrome Informed by the International Guideline 2018., 2022, , 45-51.		0
7	Changes in the prevalence of polycystic ovary syndrome in China over the past decade. The Lancet Regional Health - Western Pacific, 2022, 25, 100494.	1.3	26
8	Menstruation: where physiology, history and inequality meet. Fertility and Sterility, 2022, , .	0.5	1
9	Human growth hormone use in poor ovarian response – caution and opportunities. Therapeutic Advances in Reproductive Health, 2021, 15, 263349412199942.	1.3	3
10	Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study. Human Reproduction, 2021, 36, 1821-1831.	0.4	32
11	The Need to Reassess the Diagnosis of Polycystic Ovary Syndrome (PCOS): A Review of Diagnostic Recommendations from the International Evidence-Based Guideline for the Assessment and Management of PCOS. Seminars in Reproductive Medicine, 2021, 39, 071-077.	0.5	7
12	Intrauterine insemination (IUI) with or without letrozole for unexplained or mild male factor infertility: A randomized pilot study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 262, 216-220.	0.5	2
13	A bespoke data linkage of an IVF clinical quality registry to population health datasets; methods and performance. International Journal of Population Data Science, 2021, 6, 1679.	0.1	2
14	Higher Doses of FSH Used for Superovulation Do Not Adversely Affect Embryonic Ploidy: A Randomized Controlled Trial (STimulation Resulting in Embryonic Aneuploidy using Menopur) Tj ETQq0 0 0 rgBT	/Oveolock	102Tf 50 217
15	Truth telling in reproductive medicine. Fertility and Sterility, 2021, 116, 1464-1465.	0.5	1
16	Projecting future utilization of medically assisted fertility treatments. Population Studies, 2020, 74, 23-38.	1.1	10
17	Network meta-analyses in reproductive medicine: challenges and opportunities. Human Reproduction, 2020, 35, 1723-1731.	0.4	5
18	In-vitro maturation of oocytes versus conventional IVF in women with infertility and a high antral follicle count: a randomized non-inferiority controlled trial. Human Reproduction, 2020, 35, 2537-2547.	0.4	62

#	Article	IF	Citations
19	To share or not to share data: how valid are trials evaluating first-line ovulation induction for polycystic ovary syndrome?. Human Reproduction Update, 2020, 26, 929-941.	5.2	12
20	Development of children born from freeze-only versus fresh embryo transfer: follow-up of a randomized controlled trial. Fertility and Sterility, 2020, 114, 558-566.	0.5	14
21	Ovarian size and hormones: speaking volumes about function. Fertility and Sterility, 2020, 113, 337-338.	0.5	2
22	The BlastGen study: a randomized controlled trial of blastocyst media supplemented with granulocyte–macrophage colony-stimulating factor. Reproductive BioMedicine Online, 2020, 40, 645-652.	1.1	7
23	Assessing Whether Meditation Improves Quality of Life for Adolescent Girls With Polycystic Ovary Syndrome: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e14542.	0.5	5
24	Menstrual Cycle Length and Patterns in a Global Cohort of Women Using a Mobile Phone App: Retrospective Cohort Study. Journal of Medical Internet Research, 2020, 22, e17109.	2.1	37
25	Medical and Surgical Treatment of Reproductive Outcomes in Polycystic Ovary Syndrome: An Overview of Systematic Reviews. International Journal of Fertility & Sterility, 2020, 13, 257-270.	0.2	14
26	The Potential Role of Growth Hormone on the Endometrium in Assisted Reproductive Technology. Frontiers in Endocrinology, 2020, 11, 49.	1.5	16
27	First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. Human Reproduction Update, 2019, 25, 717-732.	5.2	71
28	Live birth rates with a freeze-only strategy versus fresh embryo transfer: secondary analysis of a randomized clinical trial. Reproductive BioMedicine Online, 2019, 38, 387-396.	1.1	17
29	Anti-Müllerian Hormone in PCOS: A Review Informing International Guidelines. Trends in Endocrinology and Metabolism, 2019, 30, 467-478.	3.1	130
30	A new evidenceâ€based guideline for assessment and management of polycystic ovary syndrome. Medical Journal of Australia, 2019, 210, 285.	0.8	13
31	Predictors of Lifestyle Intervention Attrition or Weight Loss Success in Women with Polycystic Ovary Syndrome Who Are Overweight or Obese. Nutrients, 2019, 11, 492.	1.7	34
32	Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate. Reproductive BioMedicine Online, 2019, 38, 908-915.	1.1	59
33	Lifestyle changes in women with polycystic ovary syndrome. The Cochrane Library, 2019, 2019, CD007506.	1.5	240
34	Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. The Cochrane Library, 2019, 2019, CD013505.	1.5	48
35	Societal preferences for fertility treatment in Australia: a stated preference discrete choice experiment. Journal of Medical Economics, 2019, 22, 95-107.	1.0	10
36	The effects of acupuncture on the secondary outcomes of anxiety and quality of life for women undergoing IVF: A randomized controlled trial. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 460-469.	1.3	20

#	Article	IF	Citations
37	Acupuncture performed around the time of embryo transfer: a systematic review and meta-analysis. Reproductive BioMedicine Online, 2019, 38, 364-379.	1.1	30
38	Genetics of Polycystic Ovary Syndrome. , 2019, , 447-461.		0
39	Complex diseases and co-morbidities: polycystic ovary syndrome and type 2 diabetes mellitus. Endocrine Connections, 2019, 8, R71-R75.	0.8	37
40	Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. The Cochrane Library, 2018, 2018, CD003053.	1.5	140
41	Periconception onset diabetes is associated with embryopathy and fetal growth retardation, reproductive tract hyperglycosylation and impaired immune adaptation to pregnancy. Scientific Reports, 2018, 8, 2114.	1.6	30
42	Asthma treatment impacts time to pregnancy: evidence from the international SCOPE study. European Respiratory Journal, 2018, 51, 1702035.	3.1	19
43	The impact of antenatal Bisphenol A exposure on male reproductive function at 20–22 years of age. Reproductive BioMedicine Online, 2018, 36, 340-347.	1.1	37
44	IVF Transfer of Fresh or Frozen Embryos in Women without Polycystic Ovaries. New England Journal of Medicine, 2018, 378, 137-147.	13.9	173
45	Pre-pregnancy fast food and fruit intake is associated with time to pregnancy. Human Reproduction, 2018, 33, 1063-1070.	0.4	44
46	The majority of irregular menstrual cycles in adolescence are ovulatory: results of a prospective study. Archives of Disease in Childhood, 2018, 103, 235-239.	1.0	31
47	A new evidenceâ€based guideline for assessment and management of polycystic ovary syndrome. Medical Journal of Australia, 2018, 209, 299-300.	0.8	18
48	Cost-effectiveness modelling of IVF in couples with unexplained infertility. Reproductive BioMedicine Online, 2018, 37, 555-563.	1.1	11
49	Translation and implementation of the Australianâ€led PCOS guideline: clinical summary and translation resources from the International Evidenceâ€based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Medical Journal of Australia, 2018, 209, S3-S8.	0.8	95
50	A Governance Model Addressing the Challenges of Contemporary Research. Seminars in Reproductive Medicine, 2018, 36, 073-079.	0.5	1
51	A Vision for Improving the Assessment and Management of PCOS through International Collaboration. Seminars in Reproductive Medicine, 2018, 36, 003-004.	0.5	4
52	Integrated Model of Care for Polycystic Ovary Syndrome. Seminars in Reproductive Medicine, 2018, 36, 086-094.	0.5	14
53	Successful weight loss interventions before inÂvitro fertilization: fat chance?. Fertility and Sterility, 2018, 110, 581-586.	0.5	25
54	Effect of Acupuncture vs Sham Acupuncture on Live Births Among Women Undergoing In Vitro Fertilization. JAMA - Journal of the American Medical Association, 2018, 319, 1990.	3.8	60

#	Article	IF	CITATIONS
55	Obesity and Reproduction. , 2018, , 87-93.		1
56	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility, 2018, 110, 364-379.	0.5	759
57	Forty years of IVF. Fertility and Sterility, 2018, 110, 185-324.e5.	0.5	211
58	The Possible Impact of Antenatal Exposure to Ubiquitous Phthalates Upon Male Reproductive Function at 20 Years of Age. Frontiers in Endocrinology, 2018, 9, 288.	1.5	41
59	Recommendations from the international evidenceâ€based guideline for the assessment and management of polycystic ovary syndrome. Clinical Endocrinology, 2018, 89, 251-268.	1.2	731
60	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndromeâ€â€¡. Human Reproduction, 2018, 33, 1602-1618.	0.4	1,015
61	A cost-effectiveness analysis of freeze-only or fresh embryo transfer in IVF of non-PCOS women. Human Reproduction, 2018, 33, 1907-1914.	0.4	34
62	Growth hormone in IVF cycles: any hope?. Current Opinion in Obstetrics and Gynecology, 2017, 29, 119-125.	0.9	36
63	It is ethical to recommend against assisted reproductive treatment for women with a high body mass index. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 575-578.	0.4	3
64	Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ: British Medical Journal, 2017, 356, j138.	2.4	103
65	Altered Preconception Fatty Acid Intake Is Associated with Improved Pregnancy Rates in Overweight and Obese Women Undertaking in Vitro Fertilisation. Nutrients, 2016, 8, 10.	1.7	52
66	Single embryo transfer for all?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2016, 56, 514-517.	0.4	6
67	Early Life Events Predict Adult Testicular Function; Data Derived From the Western Australian (Raine) Birth Cohort. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3333-3344.	1.8	24
68	Corticosteroid therapy in assisted reproduction $\hat{a} \in \text{``immune suppression is a faulty premise. Human Reproduction, 2016, 31, 2164-2173.}$	0.4	91
69	The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Human Reproduction Update, 2016, 22, 687-708.	5.2	440
70	Metabolic syndrome, diet and exercise. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 37, 140-151.	1.4	45
71	2015 <scp>RANZCOG A</scp> rthur <scp>W</scp> ilson <scp>M</scp> emorial <scp>O</scp> ration â€~ <scp>F</scp> rom little things, big things grow: The importance of periconception medicine'. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2015, 55, 535-540.	0.4	8
72	Mitochondrial dysfunction in oocytes of obese mothers: transmission to offspring and reversal by pharmacological endoplasmic reticulum stress inhibitors. Development (Cambridge), 2015, 142, 681-691.	1.2	223

#	Article	lF	Citations
73	Metabolic risk in PCOS: phenotype and adiposity impact. Trends in Endocrinology and Metabolism, 2015, 26, 136-143.	3.1	181
74	Expression and localisation of c-kit and KITL in the adult human ovary. Journal of Ovarian Research, 2015, 8, 31.	1.3	22
75	Distinct localisation of lipids in the ovarian follicular environment. Reproduction, Fertility and Development, 2015, 27, 593.	0.1	21
76	Mouse GDF9 decreases KITL gene expression in human granulosa cells. Endocrine, 2015, 48, 686-695.	1.1	6
77	Polycystic Ovary Syndrome: Perceptions and Attitudes of Women and Primary Health Care Physicians on Features of PCOS and Renaming the Syndrome. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E107-E111.	1.8	66
78	Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update, 2014, 20, 334-352.	5.2	389
79	Altered Glucose Metabolism in Mouse and Humans Conceived by IVF. Diabetes, 2014, 63, 3189-3198.	0.3	108
80	Impaired Glucose Metabolism in Response to High Fat Diet in Female Mice Conceived by In Vitro Fertilization (IVF) or Ovarian Stimulation Alone. PLoS ONE, 2014, 9, e113155.	1.1	24
81	Diagnosis of adolescent polycystic ovary syndrome. Steroids, 2013, 78, 751-754.	0.8	45
82	Perinatal mortality following assisted reproductive technology treatment in Australia and New Zealand, a public health approach for international reporting of perinatal mortality. BMC Pregnancy and Childbirth, 2013, 13, 177.	0.9	6
83	Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update, 2013, 19, 207-207.	5.2	6
84	Knowledge about factors that influence fertility among Australians of reproductive age: a population-based survey. Fertility and Sterility, 2013, 99, 502-507.	0.5	119
85	Small glutamine-rich tetratricopeptide repeat–containing protein alpha is present in human ovaries but may not be differentially expressed in relation to polycystic ovary syndrome. Fertility and Sterility, 2013, 99, 2076-2083.e1.	0.5	5
86	The effect of obesity on polycystic ovary syndrome: a systematic review and metaâ€analysis. Obesity Reviews, 2013, 14, 95-109.	3.1	373
87	Biomarkers of endometrial receptivity through a minimally invasive approach. Fertility and Sterility, 2013, 100, 654-655.	0.5	2
88	The longer-term health outcomes for children born as a result of IVF treatment: Part l–General health outcomes. Human Reproduction Update, 2013, 19, 232-243.	5.2	214
89	Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 2013, 19, 2-11.	5.2	62
90	The longer-term health outcomes for children born as a result of IVF treatment. Part II-Mental health and development outcomes. Human Reproduction Update, 2013, 19, 244-250.	5.2	137

#	Article	IF	Citations
91	Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 2012, 18, 618-637.	5.2	582
92	Lifestyle, periconception, and fertility., 2012, , 10-17.		0
93	The effect of diet and exercise on markers of endothelial function in overweight and obese women with polycystic ovary syndrome. Human Reproduction, 2012, 27, 2169-2176.	0.4	44
94	The FAST study: Fertility ASsessment and advice Targeting lifestyle choices and behaviours: a pilot study. Human Reproduction, 2012, 27, 2396-2404.	0.4	44
95	The Effect of Bariatric Surgery on Female Reproductive Function. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4352-4354.	1.8	15
96	Single embryo transfer reduces the risk of perinatal mortality, a population study. Human Reproduction, 2012, 27, 3609-3615.	0.4	76
97	The impact of obesity on oocytes: evidence for lipotoxicity mechanisms. Reproduction, Fertility and Development, 2012, 24, 29.	0.1	78
98	The treatment of infertility in polycystic ovary syndrome: a brief update. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2012, 52, 400-403.	0.4	62
99	Weight loss and vascular inflammatory markers in overweight women with and without polycystic ovary syndrome. Reproductive BioMedicine Online, 2012, 25, 500-503.	1.1	8
100	Endoplasmic Reticulum (ER) Stress in Cumulus-Oocyte Complexes Impairs Pentraxin-3 Secretion, Mitochondrial Membrane Potential (Î"Î"m), and Embryo Development. Molecular Endocrinology, 2012, 26, 562-573.	3.7	117
101	Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update, 2012, 18, 146-170.	5.2	367
102	Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility, 2012, 97, 28-38.e25.	0.5	1,494
103	Exposure to lipid-rich follicular fluid is associated with endoplasmic reticulum stress and impaired oocyte maturation in cumulus-oocyte complexes. Fertility and Sterility, 2012, 97, 1438-1443.	0.5	153
104	Aromatase inhibitors for PCOS: a systematic review and meta-analysis. Human Reproduction Update, 2012, 18, 301-312.	5.2	84
105	Acupuncture to improve live birth rates for women undergoing in vitro fertilization: a protocol for a randomized controlled trial. Trials, 2012, 13, 60.	0.7	23
106	Status of clomiphene citrate and metformin for infertility in PCOS. Trends in Endocrinology and Metabolism, 2012, 23, 533-543.	3.1	32
107	Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. The Cochrane Library, 2012, , CD003053.	1.5	287
108	Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine, 2012, 42, 526-534.	1.1	26

#	Article	IF	Citations
109	Molecular Filtration Properties of the Mouse Expanded Cumulus Matrix: Controlled Supply of Metabolites and Extracellular Signals to Cumulus Cells and the Oocyte1. Biology of Reproduction, 2012, 87, 89.	1.2	22
110	Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. Medical Journal of Australia, 2012, 196, 62-66.	0.8	122
111	Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Human Reproduction, 2011, 26, 2200-2208.	0.4	43
112	Obesity and Reproductive Dysfunction in Women. Endocrinology and Metabolism Clinics of North America, 2011, 40, 895-906.	1.2	31
113	Lifestyle changes in women with polycystic ovary syndrome. The Cochrane Library, 2011, , CD007506.	1.5	191
114	Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. Fertility and Sterility, 2011, 95, 2347-2353.e1.	0.5	64
115	Determinants of insulin responsiveness in young women: Impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. Nitric Oxide - Biology and Chemistry, 2011, 25, 326-330.	1.2	66
116	The power of one and its cost. Medical Journal of Australia, 2011, 195, 564-565.	0.8	4
117	Assessment and management of polycystic ovary syndrome: summary of an evidenceâ€based guideline. Medical Journal of Australia, 2011, 195, S65-112.	0.8	282
118	Does in vitro Fertilisation Increase Type 2 Diabetes and Cardiovascular Risk?. Current Diabetes Reviews, 2011, 7, 426-432.	0.6	17
119	Lifestyle changes in women with polycystic ovary syndrome. , 2011, , CD007506.		115
120	Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 2011, 17, 138-138.	5.2	2
121	Increased Beta-Oxidation and Improved Oocyte Developmental Competence in Response to L-Carnitine During Ovarian In Vitro Follicle Development in Mice. Biology of Reproduction, 2011, 85, 548-555.	1.2	97
122	Assessment of androgen concentration in women: liquid chromatography–tandem mass spectrometry and extraction RIA show comparable results. European Journal of Endocrinology, 2011, 165, 925-933.	1.9	67
123	Maternal and umbilical cord androgen concentrations do not predict digit ratio (2D:4D) in girls: A prospective cohort study. Psychoneuroendocrinology, 2010, 35, 1235-1244.	1.3	71
124	Clinical effectiveness of elective single versus double embryo transfer: meta-analysis of individual patient data from randomised trials. BMJ: British Medical Journal, 2010, 341, c6945-c6945.	2.4	310
125	Preconception lifestyle advice for people with subfertility. The Cochrane Library, 2010, , CD008189.	1.5	50
126	Beta-Oxidation Is Essential for Mouse Oocyte Developmental Competence and Early Embryo Development1. Biology of Reproduction, 2010, 83, 909-918.	1.2	324

#	Article	IF	CITATIONS
127	Polycystic ovary syndrome: steroid assessment for diagnosis. Nature Reviews Endocrinology, 2010, 6, 305-307.	4.3	3
128	Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. , 2010, , CD003053.		94
129	The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction, 2010, 25, 544-551.	0.4	1,382
130	Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 2010, 16, 347-363.	5.2	859
131	Heart rate recovery improves after weight loss in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility, 2010, 93, 1173-1178.	0.5	17
132	Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility, 2010, 94, 1812-1816.	0.5	163
133	Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertility and Sterility, 2010, 94, 1118-1121.	0.5	99
134	Circulating maternal testosterone concentrations at 18 weeks of gestation predict circulating levels of antim \tilde{A}^{1} / 4 llerian hormone in adolescence: a prospective cohort study. Fertility and Sterility, 2010, 94, 1544-1547.	0.5	39
135	The effect of modifying dietary protein and carbohydrate in weight loss on arterial compliance and postprandial lipidemia in overweight women with polycystic ovary syndrome. Fertility and Sterility, 2010, 94, 2451-2454.	0.5	12
136	Obesity on increases lipid droplets and lipotoxicity responses in the periovulatory cumulus-oocyte-complex. Fertility and Sterility, 2010, 94, S138-S139.	0.5	0
137	High-Fat Diet Causes Lipotoxicity Responses in Cumulus–Oocyte Complexes and Decreased Fertilization Rates. Endocrinology, 2010, 151, 5438-5445.	1.4	285
138	Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2038-2049.	1.8	831
139	Identification of Perilipin-2 as a lipid droplet protein regulated in oocytes during maturation. Reproduction, Fertility and Development, 2010, 22, 1262.	0.1	49
140	Obese Women Exhibit Differences in Ovarian Metabolites, Hormones, and Gene Expression Compared with Moderate-Weight Women. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1533-1540.	1.8	317
141	The effect of weight loss on anti-Mullerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Human Reproduction, 2009, 24, 1976-1981.	0.4	68
142	KIT variants in bovine ovarian cells and corpus luteum. Growth Factors, 2009, 27, 100-113.	0.5	11
143	Prenatal Determinants of Uterine Volume and Ovarian Reserve in Adolescence. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4931-4937.	1.8	46
144	Genetic and gene expression analyses of the polycystic ovary syndrome candidate gene fibrillin-3 and other fibrillin family members in human ovaries. Molecular Human Reproduction, 2009, 15, 829-841.	1.3	49

#	Article	IF	CITATIONS
145	The Relationship between Maternal and Umbilical Cord Androgen Levels and Polycystic Ovary Syndrome in Adolescence: A Prospective Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3714-3720.	1.8	125
146	Psychological Effects of Prescriptive vs General Lifestyle Advice for Weight Loss in Young Women. Journal of the American Dietetic Association, 2009, 109, 1917-1921.	1.3	26
147	Obesity and Menstrual Irregularity: Associations With SHBG, Testosterone, and Insulin. Obesity, 2009, 17, 1070-1076.	1.5	153
148	Comparison of aerobic exercise capacity and muscle strength in overweight women with and without polycystic ovary syndrome. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 1242-1250.	1.1	45
149	Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility, 2009, 91, 514-521.	0.5	84
150	The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and Sterility, 2009, 91, 456-488.	0.5	1,639
151	Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertility and Sterility, 2009, 92, 1966-1982.	0.5	337
152	Reply of the Authors: Is perifollicular vascularity assessment always feasible and clinically effective?. Fertility and Sterility, 2009, 92, e2.	0.5	0
153	Reply of the Authors: Criteria for the polycystic ovary syndrome. Fertility and Sterility, 2009, 92, e15.	0.5	2
154	Kit signaling via PI3K promotes ovarian follicle maturation but is dispensable for primordial follicle activation. Developmental Biology, 2009, 331, 292-299.	0.9	84
155	Hyperandrogenemia, psychological distress, and food cravings in young women. Physiology and Behavior, 2009, 98, 276-280.	1.0	32
156	Ovulation induction using low-dose step-up rFSH in Vietnamese women with polycystic ovary syndrome. Reproductive BioMedicine Online, 2009, 18, 516-521.	1.1	13
157	Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis, 2009, 204, 509-514.	0.4	88
158	Differences in Recognition of the 1st WHO International Reference Reagents for hCG-Related Isoforms by Diagnostic Immunoassays for Human Chorionic Gonadotropin. Clinical Chemistry, 2009, 55, 1484-1491.	1.5	114
159	Insulin-sensitising drugs for polycystic ovary syndrome. , 2009, , CD003053.		2
160	Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility., 2009,, CD003053.		43
161	Androgens and polycystic ovary syndrome. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 224-231.	1.2	91
162	FSD PHARMACOTHERAPY: Tibolone and Transdermal E2/NETA for the Treatment of Female Sexual Dysfunction in Naturally Menopausal Women: Results of a Randomized Active-Controlled Trial. Journal of Sexual Medicine, 2008, 5, 646-656.	0.3	102

#	Article	IF	Citations
163	Genome instability is increased in lymphocytes of women with polycystic ovary syndrome and is correlated with insulin resistance. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 639, 55-63.	0.4	34
164	Impact of Obesity on Female Fertility and Fertility Treatment. Women's Health, 2008, 4, 183-194.	0.7	117
165	The Effect of a Hypocaloric Diet with and without Exercise Training on Body Composition, Cardiometabolic Risk Profile, and Reproductive Function in Overweight and Obese Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3373-3380.	1.8	216
166	Effects of obesity on assisted reproductive technology outcomes. Fertility and Sterility, 2008, 89, 1611-1612.	0.5	19
167	Consensus on infertility treatment related to polycystic ovary syndrome. Fertility and Sterility, 2008, 89, 505-522.	0.5	637
168	Power Doppler assessment of follicle vascularity at the time of oocyte retrieval in in vitro fertilization cycles. Fertility and Sterility, 2008, 90, 2179-2182.	0.5	18
169	Follicle dynamics and anovulation in polycystic ovary syndrome. Human Reproduction Update, 2008, 14, 367-378.	5. 2	460
170	Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Human Reproduction Update, 2008, 15, 57-68.	5.2	87
171	Kit Ligand 2 Promotes Murine Oocyte Growth In Vitro1. Biology of Reproduction, 2008, 78, 167-175.	1.2	60
172	Dietary Therapy in Polycystic Ovary Syndrome. Seminars in Reproductive Medicine, 2008, 26, 085-092.	0.5	39
173	Human choriogonadotrophin protein core and sugar branches heterogeneity: basic and clinical insights. Human Reproduction Update, 2008, 15, 69-95.	5.2	52
174	Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal Women. Annals of Internal Medicine, 2008, 148, 569.	2.0	131
175	Peroxisome Proliferator-Activated Receptor- \hat{l}^3 Agonist Rosiglitazone Reverses the Adverse Effects of Diet-Induced Obesity on Oocyte Quality. Endocrinology, 2008, 149, 2646-2656.	1.4	200
176	Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction, 2008, 23, 1474-1474.	0.4	4
177	Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women. Menopause, 2008, 15, 1065-1069.	0.8	8
178	PPAR Gamma: Coordinating Metabolic and Immune Contributions to Female Fertility. PPAR Research, 2008, 2008, 1-19.	1.1	36
179	Effect of Testosterone Therapy versus Other Factors on the Self-reported Sexual Satisfaction of Premenopausal Women. Annals of Internal Medicine, 2008, 149, 361.	2.0	0
180	The patient with polycystic ovary syndrome. Reproductive Medicine and Assisted Reproductive Techniques Series, 2008, , 137-142.	0.1	0

#	Article	IF	Citations
181	Recommended Therapies for Metabolic Defects in Polycystic Ovary Syndrome. , 2008, , 259-279.		O
182	Expression of c-Kit receptor tyrosine kinase and effect on \hat{i}^2 -cell development in the human fetal pancreas. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E475-E483.	1.8	45
183	Obesity Management in Women with Polycystic Ovary Syndrome. Women's Health, 2007, 3, 73-86.	0.7	9
184	Insulin Resistance Increases the Risk of Spontaneous Abortion after Assisted Reproduction Technology Treatment. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1430-1433.	1.8	118
185	Abnormal Preantral Folliculogenesis in Polycystic Ovaries Is Associated with Increased Granulosa Cell Division. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4418-4426.	1.8	97
186	Impact of Lifestyle Factors on Ovarian Function and Reproductive Health in Women. Women's Health, 2007, 3, 511-513.	0.7	2
187	C-Reactive Protein before and after Weight Loss in Overweight Women with and without Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2944-2951.	1.8	59
188	Ovarian leukocyte distribution and cytokine/chemokine mRNA expression in follicular fluid cells in women with polycystic ovary syndrome. Human Reproduction, 2007, 22, 527-535.	0.4	81
189	Epidermal Growth Factor (EGF) Receptor Ligands in the Chicken Ovary: I. Evidence for Heparin-Binding EGF-Like Growth Factor (HB-EGF) as a Potential Oocyte-Derived Signal to Control Granulosa Cell Proliferation and HB-EGF and Kit Ligand Expression. Endocrinology, 2007, 148, 3426-3440.	1.4	57
190	Dietary effects on fertility treatment and pregnancy outcomes. Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 465-469.	1.2	17
191	Germline stem cells and neo-oogenesis in the adult human ovary. Developmental Biology, 2007, 306, 112-120.	0.9	119
192	Psychological benefits of a high-protein, low-carbohydrate diet in obese women with polycystic ovary syndrome—A pilot study. Appetite, 2007, 49, 590-593.	1.8	79
193	Polycystic ovary syndrome. Lancet, The, 2007, 370, 685-697.	6.3	1,245
194	The Use of Anti-Mul`llerian Hormone in Predicting Menstrual Response after Weight Loss in Overweight Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3796-3802.	1.8	46
195	Factors and perceptions that influence women's decisions to have a single embryo transferred. Reproductive BioMedicine Online, 2007, 15, 526-531.	1.1	29
196	Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome. American Journal of Clinical Nutrition, 2007, 86, 1603-1610.	2.2	76
197	Glucose tolerance abnormalities in Australian women with polycystic ovary syndrome. Medical Journal of Australia, 2007, 187, 328-331.	0.8	32
198	Quality management systems in ART: are they really needed? An Australian clinic's experience. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2007, 21, 41-55.	1.4	3

#	Article	IF	CITATIONS
199	Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome. American Journal of Clinical Nutrition, 2007, 86, 1603-1610.	2.2	30
200	Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4237-4245.	1.8	1,811
201	Introduction: diet, nutrition and exercise in reproduction. Reproductive BioMedicine Online, 2006, 12, 524-525.	1.1	0
202	Effects of lifestyle modification in polycystic ovarian syndrome. Reproductive BioMedicine Online, 2006, 12, 569-578.	1.1	114
203	Diagnosis and Management of Polycystic Ovary Syndrome. Drugs, 2006, 66, 903-912.	4.9	46
204	Oocyte-granulosa cell interactions during mouse follicular development: regulation of kit ligand expression and its role in oocyte growth. Reproductive Biology and Endocrinology, 2006, 4, 19.	1.4	170
205	Influence of acupuncture stimulation on pregnancy rates for women undergoing embryo transfer. Fertility and Sterility, 2006, 85, 1352-1358.	0.5	123
206	Effect of a very-low-calorie diet on in vitro fertilization outcomes. Fertility and Sterility, 2006, 86, 227-229.	0.5	72
207	Reducing multiple pregnancy from assisted reproduction treatment: educating patients and medical staff. Medical Journal of Australia, 2006, 184, 180-181.	0.8	15
208	Short-term meal replacements followed by dietary macronutrient restriction enhance weight loss in polycystic ovary syndrome. American Journal of Clinical Nutrition, 2006, 84, 77-87.	2.2	113
209	Prevention of multiple gestation in IVF: Introduction to Theme. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2006, 46, S14-S16.	0.4	0
210	Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome. BJOG: an International Journal of Obstetrics and Gynaecology, 2006, 113, 1308-1314.	1.1	39
211	Lifestyle Choices, Diet, and Insulin Sensitizers in Polycystic Ovary Syndrome. Endocrine, 2006, 30, 35-44.	2.2	21
212	Polycystic ovarian syndrome – prognosis and outcomes. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2006, 20, 751-778.	1.4	52
213	Kit ligand and c-Kit are expressed during early human ovarian follicular development and their interaction is required for the survival of follicles in long-term culture. Reproduction, 2006, 131, 641-649.	1.1	99
214	A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. Human Reproduction, 2006, 21, 95-103.	0.4	82
215	Epigenetic Modification of the X Chromosome Influences Susceptibility to Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2789-2791.	1.8	68
216	Nutrition and reproduction in women. Human Reproduction Update, 2006, 12, 193-207.	5.2	221

#	Article	IF	Citations
217	Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis. Molecular Human Reproduction, 2006, 12, 61-69.	1.3	165
218	Troglitazone Regulates Peroxisome Proliferator-Activated Receptors and Inducible Nitric Oxide Synthase in Murine Ovarian Macrophages 1. Biology of Reproduction, 2006, 74, 153-160.	1.2	29
219	KIT/KIT Ligand in Mammalian Oogenesis and Folliculogenesis: Roles in Rabbit and Murine Ovarian Follicle Activation and Oocyte Growth1. Biology of Reproduction, 2006, 75, 421-433.	1.2	104
220	The Kit ligand/c-Kit receptor system in goat ovaries: gene expression and protein localization. Zygote, 2006, 14, 317-328.	0.5	27
221	Obesity, polycystic ovary syndrome, infertility treatment: Lifestyle modification is paramount. BMJ: British Medical Journal, 2006, 332, 609.2.	2.4	10
222	Anti-apoptotic action of stem cell factor on oocytes in primordial follicles and its signal transduction. Molecular Reproduction and Development, 2005, 70, 82-90.	1.0	80
223	Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clinical Endocrinology, 2005, 62, 289-295.	1.2	107
224	Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate, 2005, 63, 19-28.	1.2	103
225	Androgens Augment the Mitogenic Effects of Oocyte-Secreted Factors and Growth Differentiation Factor 9 on Porcine Granulosa Cells1. Biology of Reproduction, 2005, 73, 825-832.	1.2	109
226	Adipokines: implications for female fertility and obesity. Reproduction, 2005, 130, 583-597.	1.1	227
227	Effect of a Synthetic Progestin on the Exercise Status of Sedentary Young Women. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3830-3837.	1.8	22
228	Towards less confusing terminology in reproductive medicine. Human Reproduction, 2005, 20, 2669-2671.	0.4	8
229	Insulin-sensitisers in the treatment of polycystic ovary syndrome. Expert Opinion on Pharmacotherapy, 2005, 6, 2419-2427.	0.9	14
230	Signal transduction of stem cell factor in promoting early follicle development. Molecular and Cellular Endocrinology, 2005, 229, 3-10.	1.6	27
231	In vitro growth of oocytes from primordial follicles isolated from frozen–thawed lamb ovaries. Theriogenology, 2005, 64, 1357-1370.	0.9	55
232	Stem cell factor and c-Kit in human primordial germ cells and fetal ovaries. Molecular and Cellular Endocrinology, 2005, 234, 1-10.	1.6	101
233	Recombinant or urinary gonadotrophins – an Australian perspective. Reproductive BioMedicine Online, 2005, 11, 542-543.	1.1	3
234	4: Polycystic ovary syndrome. Medical Journal of Australia, 2004, 180, 132-137.	0.8	61

#	Article	IF	Citations
235	Chrelin and Measures of Satiety Are Altered in Polycystic Ovary Syndrome But Not Differentially Affected by Diet Composition. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3337-3344.	1.8	142
236	The Carboxyterminal Peptide of Chorionic Gonadotropin Facilitates Activation of the Marmoset LH Receptor. Experimental and Clinical Endocrinology and Diabetes, 2004, 112, 574-579.	0.6	20
237	Improving reproductive performance in overweight/obese women with effective weight management. Human Reproduction Update, 2004, 10, 267-280.	5.2	320
238	Macrophage contributions to ovarian function. Human Reproduction Update, 2004, 10, 119-133.	5.2	277
239	Establishment, Value Assignment, and Characterization of New WHO Reference Reagents for Six Molecular Forms of Human Chorionic Gonadotropin. Clinical Chemistry, 2004, 51, 177-182.	1.5	60
240	Interactions Between Androgen and Growth Factors in Granulosa Cell Subtypes of Porcine Antral Follicles 1. Biology of Reproduction, 2004, 71, 45-52.	1.2	68
241	Metformin—Comparison with Other Therapies in Ovulation Induction in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4797-4800.	1.8	34
242	Chorionic gonadotrophin beta subunit mRNA but not luteinising hormone beta subunit mRNA is expressed in the pituitary of the common marmoset (Callithrix jacchus). Journal of Molecular Endocrinology, 2004, 32, 115-128.	1.1	73
243	Incidence of spontaneous abortion among pregnancies produced by assisted reproductive technology. Human Reproduction, 2004, 19, 272-277.	0.4	122
244	What should we do with donated embryos that may be genetically affected?. Human Reproduction, 2004, 19, 1065-1068.	0.4	7
245	Periovulatory Expression of Intercellular Adhesion Molecule-1 in the Rat Ovary1. Biology of Reproduction, 2004, 71, 1384-1390.	1.2	19
246	Stockpiling of Transitional and Classic Primary Follicles in Ovaries of Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5321-5327.	1.8	194
247	Single or multiple embryo transfer following in vitro fertilisation for improved neonatal outcome: A systematic review of the literature. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2004, 44, 283-291.	0.4	19
248	The expression patterns of mRNA-encoding stem cell factor, internal stem cell factor and c-kit in the prepubertal and adult porcine ovary. Journal of Anatomy, 2004, 205, 393-403.	0.9	22
249	Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2004, 18, 719-736.	1.4	65
250	Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction, 2004, 19, 41-47.	0.4	4,780
251	Risk factors for the deterioration of glucose metabolism in polycystic ovary syndrome. Reproductive BioMedicine Online, 2004, 9, 201-204.	1.1	8
252	What is the most relevant standard of success in assisted reproduction?: Assessing the BESST index for reproduction treatment. Human Reproduction, 2004, 19, 1049-1051.	0.4	24

#	Article	IF	CITATIONS
253	Polycystic ovary syndromeâ€"diagnosis and etiology. International Congress Series, 2004, 1266, 225-232.	0.2	3
254	Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 2004, 81, 19-25.	0.5	5,122
255	The potential danger of COX-2 inhibitors. Fertility and Sterility, 2004, 81, 493-494.	0.5	29
256	Overweight infertile patients have a higher fecundity than normal-weight women undergoing controlled ovarian hyperstimulation with intrauterine insemination. Fertility and Sterility, 2004, 81, 1710-1712.	0.5	29
257	Expression of stem cell factor and its receptor in human fetal and adult ovaries. Fertility and Sterility, 2004, 82, 1235-1243.	0.5	26
258	Should we continue or stop insulin sensitizing drugs during pregnancy?. Current Opinion in Obstetrics and Gynecology, 2004, 16, 245-250.	0.9	56
259	The Menstrual Cycle or Oral Contraceptive Pill. Medicine and Science in Sports and Exercise, 2004, 36, S280.	0.2	1
260	Impact of menstrual cycle phase on the exercise status of young, sedentary women. European Journal of Applied Physiology, 2003, 90, 505-513.	1.2	39
261	Risk of multiple pregnancy when infertility is treated with ovulation induction by gonadotropins. Fertility and Sterility, 2003, 80, 664-665.	0.5	8
262	Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ: British Medical Journal, 2003, 327, 951-0.	2.4	630
263	Formation and early development of follicles in the polycystic ovary. Lancet, The, 2003, 362, 1017-1021.	6.3	412
264	Dietary Composition in Restoring Reproductive and Metabolic Physiology in Overweight Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 812-819.	1.8	447
265	Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. The Cochrane Library, 2003, , CD003053.	1.5	126
266	Preparation and Characterization of New WHO Reference Reagents for Human Chorionic Gonadotropin and Metabolites. Clinical Chemistry, 2003, 49, 144-154.	1.5	103
267	Leptin and Leptin Receptor Expression in the Rat Ovary. Endocrinology, 2003, 144, 5006-5013.	1.4	66
268	Different fertilization rates between immotile testicular spermatozoa and immotile ejaculated spermatozoa for ICSI in men with Kartagener's syndrome: case reports. Human Reproduction, 2003, 18, 1286-1288.	0.4	46
269	The Role of Leptin in Polycystic Ovary Syndrome. , 2003, , 333-345.		1
270	Preimplantation genetic diagnosis for beta-thalassaemia using sequencing of single cell PCR products to detect mutations and polymorphic loci. Molecular Human Reproduction, 2002, 8, 1136-1143.	1.3	31

#	Article	IF	CITATIONS
271	The effect of various infertility treatments on the risk of preterm birth. Human Reproduction, 2002, 17, 945-949.	0.4	118
272	A randomized controlled trial of a soft double lumen embryo transfer catheter versus a firm single lumen catheter: significant improvements in pregnancy rates. Human Reproduction, 2002, 17, 1502-1506.	0.4	35
273	Soluble adhesion molecules in serum throughout the menstrual cycle. Human Reproduction, 2002, 17, 2272-2278.	0.4	28
274	Expression of Leptin and Its Receptor in the Murine Ovary: Possible Role in the Regulation of Oocyte Maturation1. Biology of Reproduction, 2002, 66, 1548-1554.	1.2	117
275	Early pregnancy loss following assisted reproductive technology treatment. Human Reproduction, 2002, 17, 3220-3223.	0.4	194
276	In Vitro Development of Growing Oocytes from Fetal Mouse Oocytes: Stage-Specific Regulation by Stem Cell Factor and Granulosa Cells. Developmental Biology, 2002, 244, 85-95.	0.9	103
277	Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet, The, 2002, 359, 673-674.	6.3	146
278	Neurological sequelae in in-vitro fertilisation babies. Lancet, The, 2002, 360, 718-719.	6.3	8
279	The role of lifestyle modification in polycystic ovary syndrome. Trends in Endocrinology and Metabolism, 2002, 13, 251-257.	3.1	272
280	Programming and reproductive functioning. Trends in Endocrinology and Metabolism, 2002, 13, 386-392.	3.1	102
281	Hyperandrogenaemia and the ovary. Molecular and Cellular Endocrinology, 2002, 191, 113-119.	1.6	16
282	The Obese Patient with Infertility: A Practical Approach to Diagnosis and Treatment. Nutrition in Clinical Care: an Official Publication of Tufts University, 2002, 5, 290-297.	0.2	34
283	Obesity Increases the Risk of Spontaneous Abortion during Infertility Treatment. Obesity, 2002, 10, 551-554.	4.0	228
284	The Endocrine Basis for Spontaneous Ovulation, Ovulation Induction and Controlled Superovulation., 2002,, 11-42.		2
285	Reproductive consequences of COX-2 inhibition. Lancet, The, 2001, 358, 1287-1288.	6.3	41
286	Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Human Reproduction, 2001, 16, 2606-2609.	0.4	194
287	Metformin and intervention in polycystic ovary syndrome. Medical Journal of Australia, 2001, 174, 580-583.	0.8	19
288	Obesity, polycystic ovary syndrome and anovulation - how are they interrelated?. Current Opinion in Obstetrics and Gynecology, 2001, 13, 323-327.	0.9	21

#	Article	IF	Citations
289	Circulating follistatin concentrations are higher and activin concentrations are lower in polycystic ovarian syndrome. Human Reproduction, 2001, 16, 668-672.	0.4	78
290	Granulocyte-Macrophage Colony-Stimulating Factor Promotes Glucose Transport and Blastomere Viability in Murine Preimplantation Embryos 1. Biology of Reproduction, 2001, 64, 1206-1215.	1.2	165
291	Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Human Reproduction, 2001, 16, 1995-1998.	0.4	307
292	Establishment and Characterization of a Steroidogenic Human Granulosa-Like Tumor Cell Line, KGN, That Expresses Functional Follicle-Stimulating Hormone Receptor. Endocrinology, 2001, 142, 437-445.	1.4	76
293	Kit ligand actions on ovarian stromal cells: Effects on theca cell recruitment and steroid production., 2000, 55, 55-64.		114
294	Oocyte-Secreted Factor(s) Determine Functional Differences Between Bovine Mural Granulosa Cells and Cumulus Cells1. Biology of Reproduction, 2000, 63, 839-845.	1.2	165
295	Body mass and probability of pregnancy during assisted reproduction treatment: retrospective study. BMJ: British Medical Journal, 2000, 321, 1320-1321.	2.4	275
296	The effect of intercourse on pregnancy rates during assisted human reproduction. Human Reproduction, 2000, 15, 2653-2658.	0.4	192
297	Characterization of Ovarian Function in Granulocyte-Macrophage Colony-Stimulating Factor-Deficient Mice1. Biology of Reproduction, 2000, 62, 704-713.	1.2	38
298	hCGbeta core fragment is a metabolite of hCG: evidence from infusion of recombinant hCG. Journal of Endocrinology, 2000, 164, 299-305.	1.2	25
299	Intrabursal Injection of Clodronate Liposomes Causes Macrophage Depletion and Inhibits Ovulation in the Mouse Ovary1. Biology of Reproduction, 2000, 62, 1059-1066.	1.2	76
300	The in Vivo and in Vitro Effects of Exogenous Leptin on Ovulation in the Rat*. Endocrinology, 2000, 141, 1971-1976.	1.4	162
301	The in Vivo and in Vitro Effects of Exogenous Leptin on Ovulation in the Rat. Endocrinology, 2000, 141, 1971-1976.	1.4	63
302	Effect of granulocyte-macrophage colony-stimulating factor deficiency on ovarian follicular cell function. Reproduction, 2000, , 283-292.	1.1	10
303	Thirty-seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8573-8578.	3.3	437
304	Size at birth and plasma leptin concentrations in adult life. International Journal of Obesity, 1999, 23, 1025-1029.	1.6	86
305	Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene, 1999, 18, 5573-5581.	2.6	87
306	What is the best strategy for using embryos and presenting results in assisted reproductive technology? A strategy for valid comparisons of results. Journal of Assisted Reproduction and Genetics, 1999, 16, 471-473.	1.2	0

#	Article	IF	CITATIONS
307	Polcystic ovary syndrome and implications for the menopause. Climacteric, 1999, 2, 141-143.	1.1	8
308	Variations in peripheral blood levels of immunoreactive tumor necrosis factor \hat{l}_{\pm} (TNF \hat{l}_{\pm}) throughout the menstrual cycle and secretion of TNF \hat{l}_{\pm} from the human corpus luteum. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1999, 83, 213-217.	0.5	68
309	Characterization of the translated products of the alternatively spliced luteinizing hormone receptor in the ovine ovary throughout the oestrous cycle. Molecular and Cellular Endocrinology, 1999, 147, 113-124.	1.6	14
310	Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. The Cochrane Library, 1999, , CD001018.	1.5	48
311	Colony stimulating factor-1 concentrations in blood and follicular fluid during the human menstrual cycle and ovarian stimulation: possible role in the ovulatory process. Human Reproduction, 1999, 14, 1302-1306.	0.4	23
312	No association between the 308 polymorphism in the tumour necrosis factor alpha (TNFalpha) promoter region and polycystic ovaries. Molecular Human Reproduction, 1999, 5, 5-9.	1.3	50
313	Oocyte Regulation of Kit Ligand Expression in Mouse Ovarian Follicles. Developmental Biology, 1999, 214, 342-353.	0.9	156
314	Restoration of Reproductive Potential by Lifestyle Modification in Obese Polycystic Ovary Syndrome: Role of Insulin Sensitivity and Luteinizing Hormone. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1470-1474.	1.8	334
315	Augmented Androgen Production Is a Stable Steroidogenic Phenotype of Propagated Theca Cells from Polycystic Ovaries. Molecular Endocrinology, 1999, 13, 946-957.	3.7	95
316	Towards an epidemiologic definition of renal disease: Rates and associations of albuminuria in a high-risk Australian Aboriginal community. Nephrology, 1998, 4, S59-S65.	0.7	6
317	Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Human Reproduction, 1998, 13, 1502-1505.	0.4	703
318	Effects of Interleukin (IL)-6 on Luteinizing Hormone- and IL- $1\hat{l}^2$ -Induced Ovulation and Steroidogenesis in the Rat Ovary1. Biology of Reproduction, 1998, 58, 1266-1271.	1.2	45
319	Consequences of exclusive expression in vivo of kit-ligand lacking the major proteolytic cleavage site. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11903-11908.	3.3	85
320	Expression, characterisation and immunoassay of recombinant marmoset chorionic gonadotrophin dimer and beta-subunit. Journal of Endocrinology, 1998, 159, 141-151.	1.2	6
321	Obesity and reproductive disorders: a review. Reproduction, Fertility and Development, 1998, 10, 55.	0.1	221
322	Expression of c-kit Messenger Ribonucleic Acid in Human Oocyte and Presence of Soluble c-kit in Follicular Fluid. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1239-1242.	1.8	16
323	Expression of the ovine stem cell factor gene during folliculogenesis in late fetal and adult ovaries. Journal of Molecular Endocrinology, 1997, 18, 127-135.	1.1	32
324	Localisation of mRNA for interleukin-1 receptor and interleukin-1 receptor antagonist in the rat ovary. Journal of Endocrinology, 1997, 152, 11-17.	1.2	36

#	Article	IF	CITATIONS
325	Intrauterine insemination: effect of the temporal relationship between the luteinizing hormone surge, human chorionic gonadotrophin administration and insemination on pregnancy rates. Human Reproduction, 1997, 12, 2162-2166.	0.4	35
326	A health profile of adults in a Northern Territory Aboriginal community, with an emphasis on preventable morbidities. Australian and New Zealand Journal of Public Health, 1997, 21, 121-126.	0.8	76
327	Ovarian function in the GM-CSF deficient mouse. Journal of Reproductive Immunology, 1997, 34, 77.	0.8	0
328	Circulating leptin concentrations in polycystic ovary syndrome: relation to anthropometric and metabolic parameters. Clinical Endocrinology, 1997, 46, 175-181.	1.2	100
329	Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertility and Sterility, 1996, 66, 942-947.	0.5	124
330	Cytokines in the ovary: Pathophysiology and potential for pharmacological intervention., 1996, 69, 219-236.		46
331	Inhibition of Nitric Oxide: Effects on Interleukin-lî²-Enhanced Ovulation Rate, Steroid Hormones, and Ovarian Leukocyte Distribution at Ovulation in the Rat1. Biology of Reproduction, 1996, 54, 436-445.	1.2	166
332	Granulocyte-macrophage colony-stimulating factor: presence in human follicular fluid, protein secretion and mRNA expression by ovarian cells. Molecular Human Reproduction, 1996, 2, 555-562.	1.3	36
333	Ethnic differences in insulin and glucose response to glucose between white and Indian women with polycystic ovary syndrome. Fertility and Sterility, 1995, 63, 58-62.	0.5	94
334	Metabolic approaches to the subclassification of polycystic ovary syndrome. Fertility and Sterility, 1995, 63, 329-335.	0.5	84
335	Cellular composition of primary cultures of human granulosa-lutein cells and the effect of cytokines on cell proliferation. Reproduction, Fertility and Development, 1995, 7, 21.	0.1	12
336	Luteinizing Hormone/Chorionic Gonadotropin Bioactivity in the Common Marmoset (Callithrixjacchus) is Due to a Chorionic Gonadotropin Molecule with a Structure Intermediate between Human Chorionic Gonadotropin and Human Luteinizing Hormone. Biology of Reproduction, 1995, 53, 380-389.	1.2	34
337	Reduction of ovulation rate in the rat by administration of a neutrophil-depleting monoclonal antibody. Journal of Reproductive Immunology, 1995, 29, 265-270.	0.8	68
338	Rat Ovary Produces Cytokines during Ovulation1. Biology of Reproduction, 1994, 50, 88-94.	1.2	121
339	Localization of leukocyte subsets in the follicle wall and in the corpus luteum throughout the human menstrual cycle. Fertility and Sterility, 1994, 61, 488-495.	0.5	208
340	Effects of Cytokines on Prostaglandin Production and Steroidogenesis of Incubated Preovulatory Follicles of the Rat1. Biology of Reproduction, 1993, 48, 165-171.	1.2	97
341	Tumor necrosis factor \hat{l}_{\pm} in the human ovary: presence in follicular fluid and effects on cell proliferation and prostaglandin production. Fertility and Sterility, 1992, 58, 934-940.	0.5	122
342	Choriogonadotropin-mediated thyrotoxicosis in a man. Clinical Chemistry, 1991, 37, 1127-1131.	1.5	17

#	Article	IF	CITATIONS
343	Steel-Dickie mutation encodes a c-kit ligand lacking transmembrane and cytoplasmic domains Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 4671-4674.	3.3	286
344	Decrease in luteal gonadotropin concentrations in conception cycles after in vitro fertilization/gamete intrafallopian transfer. Fertility and Sterility, 1991, 55, 125-130.	0.5	4
345	Expression and function of c-kit in hemopoietic progenitor cells Journal of Experimental Medicine, 1991, 174, 63-71.	4.2	696
346	Lymphokines, Including Interleukin-2, Alter Gonadotropin-Stimulated Progesterone Production and Proliferation of Human Granulosa-Luteal Cells <i>in Vitro</i> *. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 824-831.	1.8	56
347	When a positive pregnancy test isn't. Medical Journal of Australia, 1991, 154, 718-719.	0.8	2
348	Prostaglandins in dysfunctional labour; evidence for altered production of prostaglandin F2 alpha. Reproduction, Fertility and Development, 1990, 2, 563.	0.1	7
349	Luteal function associated with single, multiple and ectopic embryo implantation in natural cycles or after ovarian hyperstimulation for in-vitro fertilization/gamete intra-Fallopian transfer. Human Reproduction, 1990, 5, 476-480.	0.4	12
350	Measurement of Human Chorionic Gonadotrophin (hCG): Indications and Techniques for the Clinical Laboratory. Annals of Clinical Biochemistry, 1990, 27, 183-194.	0.8	20
351	Metabolic Profiles and Lipoprotein Lipid Concentrations in Non-Obese and Obese Patients with Polycystic Ovarian Disease. Hormone and Metabolic Research, 1990, 22, 537-540.	0.7	42
352	Increased and intermittent prostaglandin release from amnion detected by a new superfusion technique for full thickness fetal membrane. Prostaglandins, 1990, 39, 601-610.	1.2	6
353	Detection of a small molecular species of human chorionic gonadotropin in the urine of patients with carcinoma of the cervix and cervical intraepithelial neoplasia: Comparison with other assays for human chorionic gonadotropin and its fragments. Gynecologic Oncology, 1990, 37, 254-259.	0.6	14
354	Insulin and C-Peptide Secretion in Non-Obese Patients with Polycystic Ovarian Disease. Hormone and Metabolic Research, 1989, 21, 502-506.	0.7	32
355	Analytical and clinical sensitivity and specificity in pregnancy testing. American Journal of Obstetrics and Gynecology, 1989, 161, 835.	0.7	0
356	The role of prostaglandins in the inhibition of cultured carcinoma cell growth produced by gamma-linolenic acid. Prostaglandins Leukotrienes and Essential Fatty Acids, 1989, 35, 119-123.	1.0	10
357	Attempts at dietary alteration of prostaglandin pathways in the management of pre-eclampsia. Prostaglandins Leukotrienes and Essential Fatty Acids, 1989, 37, 145-147.	1.0	16
358	Changes in the binding characteristics of oestrogen and progesterone in uterine and intrauterine tissue with the progression of human pregnancy. The Journal of Steroid Biochemistry, 1989, 33, 535-540.	1.3	4
359	Plasma Cxwcentraticns of Calcium Ions in African Women with Eclampsia. Clinical and Experimental Hypertension Part B, Hypertension in Pregnancy, 1989, 8, 583-591.	0.2	0
360	SPECTRUM OF THYROID FUNCTION ABNORMALITIES IN GESTATIONAL TROPHOBLASTIC NEOPLASIA. Clinical Endocrinology, 1988, 29, 583-592.	1.2	41

#	Article	IF	CITATIONS
361	Intrauterine pressure studies in multigravid patients in spontaneous labour: effect of oxytocin augmentation in delayed first stage. BJOG: an International Journal of Obstetrics and Gynaecology, 1988, 95, 771-777.	1.1	6
362	Serial oxytocin levels in amniotic fluid and maternal plasma during normal and induced labour. BJOG: an International Journal of Obstetrics and Gynaecology, 1988, 95, 888-893.	1.1	13
363	Treatment of menstrually induced acute intermittent porphyria by a long-acting gonadotrophin-releasing hormone agonist (D Trp6-Pro9 N ethylamide) LHRH. Case report. BJOG: an International Journal of Obstetrics and Gynaecology, 1988, 95, 192-194.	1.1	6
364	Impaired Corpus Luteum Function in Ectopic Pregnancy Cannot be Explained by Altered Human Chorionic Gonadotropin. Journal of Clinical Endocrinology and Metabolism, 1988, 66, 1166-1170.	1.8	37
365	Effects of severe post partum haemorrhage on puerperal pituitary function. Journal of Obstetrics and Gynaecology, 1987, 7, 197-200.	0.4	1
366	Bedside Application of an Ultrasensitive Urine Test for HCG in Patients with Suspected Ectopic Pregnancy. Annals of Clinical Biochemistry, 1987, 24, 268-272.	0.8	8
367	Differential regulation of prostaglandin production by inhibitors and stimulators in amiotic fluids during normal and dysfunctional labor. Prostaglandins, 1987, 34, 477-491.	1.2	4
368	Decreased concentrations and affinities of oestrogen and progesterone receptors of intrauterine tissue in human pregnancy. The Journal of Steroid Biochemistry, 1987, 26, 473-479.	1.3	27
369	Amniotic Membrane Production of Prostaglandin F _{2<i>α</i>} Is Reduced in Dysfunctional Human Labor: Results of <i>in Vivo</i> >and <i>in Vitro</i> Studies. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 1000-1005.	1.8	8
370	Laboratory Apparatus for Preparing and Dispensing Nitrogen-15-labeled Anhydrous Ammonia. Soil Science Society of America Journal, 1986, 50, 238-242.	1.2	2
371	Sensitive urine tests and human chorionic gonadotrophin secreted during ectopic pregnancy BMJ: British Medical Journal, 1986, 292, 590-591.	2.4	9
372	Urinary hCG Test in Ectopic Pregnancy. Fertility and Sterility, 1986, 45, 306-308.	0.5	0
373	Amniotic Fluid Prostacyclin in African Women with Eclampsia. Clinical and Experimental Hypertension Part B, Hypertension in Pregnancy, 1986, 5, 29-37.	0.2	O
374	Free subunits of human chorionic gonadotropin do not respond to intravenous injection of thyrotropin releasing hormone. Journal of Obstetrics and Gynaecology, 1986, 7, 141-142.	0.4	0
375	Maturation of Startle Modulation. Psychophysiology, 1986, 23, 624-634.	1.2	95
376	Male transmission of the gene for isolated gonadotropin-releasing hormone deficiency. Fertility and Sterility, 1985, 43, 225-228.	0.5	0
377	Immunoreactive oestrogens and progesterone in amniotic fluid in twin pregnancies. BJOG: an International Journal of Obstetrics and Gynaecology, 1985, 92, 216-219.	1.1	1
378	HUMAN CHORIONIC GONADOTROPHIN AND SUBUNITS—HETEROGENEITY IN SERUM OF MALE PATIENTS WITH TUMOURS OF THE GENITAL TRACT. Clinical Endocrinology, 1985, 23, 25-34.	1,2	37

#	Article	IF	Citations
379	Monoclonal Antibodies to Human Chorionic Gonadotropin: Implications for Antigenic Mapping, Immunoradiometric Assays, and Clinical Applications**. Journal of Clinical Endocrinology and Metabolism, 1985, 61, 1031-1038.	1.8	55
380	Pregnancy-induced hypertension in twin pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 1984, 91, 240-243.	1.1	25
381	Umbilical artery concentrations of androstenedione increase in early labour in the leading twin fetus. BJOG: an International Journal of Obstetrics and Gynaecology, 1984, 91, 776-780.	1.1	10
382	Abnormal concentrations of prostaglandins in amniotic fluid during delayed labour in multigravid patients. BJOG: an International Journal of Obstetrics and Gynaecology, 1984, 91, 781-787.	1.1	20
383	Central venous concentrations of immunoreactive prostaglandins E, F, and 6-keto-prostaglandin F1 in eclampsia BMJ: British Medical Journal, 1984, 288, 1487-1489.	2.4	17
384	Twin pregnancy as a model for studies in fetal cortisol concentrations in labour: relation to prostaglandins, prolactin and ACTH. BJOG: an International Journal of Obstetrics and Gynaecology, 1983, 90, 1033-1039.	1.1	12
385	Amniotic fluid phospholipids and glucocorticoids in multiple pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 1983, 90, 51-55.	1.1	16
386	Consumptive coagulopathy following fetal death in a triplet pregnancy. American Journal of Obstetrics and Gynecology, 1982, 142, 595-596.	0.7	59
387	Morphology and Morphogenesis of the Stein-Leventhal Ovary and of So-called "Hyperthecosis― Obstetrical and Gynecological Survey, 1982, 37, 59-77.	0.2	375
388	Fetal urinary prostaglandins. Prostaglandins, Leukotrienes, and Medicine, 1982, 8, 171-172.	0.8	8
389	HYPERTHYROIDISM IN GESTATIONAL TROPHOBLASTIC NEOPLASIA. Clinical Endocrinology, 1981, 15, 395-401.	1.2	48
390	Fetal prostaglandin levels in twin pregnancies. Prostaglandins, Leukotrienes and Essential Fatty Acids, 1981, 6, 309-316.	1.2	17
391	THE MANAGEMENT OF CHORIOCARCINOMA CAUSING SEVERE THYROTOXICOSIS. TWO CASE REPORTS. BJOG: an International Journal of Obstetrics and Gynaecology, 1981, 88, 938-943.	1.1	14
392	Classical eyeblink conditioning in the bilaterally hemispherectomized cat. Experimental Neurology, 1974, 44, 363-380.	2.0	63
393	Enhanced go, no-go single-lever alternation of mice with septal lesions Journal of Comparative and Physiological Psychology, 1971, 75, 508-512.	1.8	12
394	Pre-pregnancy counseling and treatment. , 0, , 5-18.		0
395	Obesity and oocyte quality. , 0, , 362-370.		1
396	A patient found to have Cushing syndrome. , 0, , 50-52.		0

#	Article	IF	CITATIONS
397	Postpartum pituitary problems. , 0, , 53-55.		0
398	Mild-approach ART in a patient with polycystic ovary syndrome. , 0, , 93-96.		0
399	A slim patient with polycystic ovary syndrome (PCOS). , 0, , 97-101.		0
400	Direct Actions of Kit-Ligand on Theca Cell Growth and Differentiation During Follicle Development. , 0, .		28